MDWD
Closed
Mediwound Ltd
19.2
-0.2 (-1.03%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 19.37
Day's Range: 18.97 - 19.5399
Send
sign up or login to leave a comment!
When Written:
12.61
Mediwound Ltd is a biopharmaceutical company that develops, manufactures, and commercializes innovative therapies for severe burn and wound management. The company was founded in 2001 and is headquartered in Yavne, Israel.
Mediwound's lead product, NexoBrid, is a topical enzymatic debridement agent that removes dead or damaged tissue from severe burns. NexoBrid has been approved for use in Europe, Israel, and other countries and is currently undergoing clinical trials in the United States.
In addition to NexoBrid, Mediwound is also developing other wound care products, including EscharEx, a topical treatment for chronic and hard-to-heal wounds.
Mediwound has partnerships with several leading pharmaceutical companies, including Allergan, Teva Pharmaceutical Industries, and Vericel Corporation. The company is publicly traded on the NASDAQ under the ticker symbol MDWD.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Mediwound's lead product, NexoBrid, is a topical enzymatic debridement agent that removes dead or damaged tissue from severe burns. NexoBrid has been approved for use in Europe, Israel, and other countries and is currently undergoing clinical trials in the United States.
In addition to NexoBrid, Mediwound is also developing other wound care products, including EscharEx, a topical treatment for chronic and hard-to-heal wounds.
Mediwound has partnerships with several leading pharmaceutical companies, including Allergan, Teva Pharmaceutical Industries, and Vericel Corporation. The company is publicly traded on the NASDAQ under the ticker symbol MDWD.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!